Hansa Biopharma AB (publ) (STO:HNSA)

Sweden · Delayed Price · Currency is SEK

29.94

+0.46 (1.56%)

Apr 14, 2026, 5:29 PM CET

Revenue by Segment

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Research and Development for Production of Pharmaceuticals			134.09M	154.53M	33.88M	6.10M	3.36M
Research and Development for Production of Pharmaceuticals Growth			-13.22%	356.12%	455.56%	81.27%	0.18%
Total			134.09M	154.53M	33.88M	6.10M	3.36M
Total Growth			-13.22%	356.12%	455.56%	81.27%	0.18%

Revenue by Geography

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016
Sweden			-	4.68M	-	6.10M	-
North America			27.42M	64.27M	15.71M	-	-
North America Growth			-57.34%	309.12%	-	-	-
Europe (Ex Sweden)			106.68M	85.57M	18.17M	-	-
Europe (Ex Sweden) Growth			24.66%	371.01%	-	-	-
Total			134.09M	154.52M	33.88M	6.10M	-
Total Growth			-13.22%	356.12%	455.56%	-	-

Source: S&P Global Market Intelligence.